Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
Clinical trial NCT02621151 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02621151
- Sponsor
- NYU Langone Health
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-11
- Primary completion
- 2022-11-10
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.